


8. Shimamoto K, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, et al. Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: Implications from the Japan Lipid Intervention Trial. *Hypertens Res* 2007; **30**: 119–123.
9. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, et al. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; **344**: 1383–1389.
10. Todd PA, Goa KL. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. *Drugs* 1990; **40**: 583–587.
11. Christolm A, Mann J, Sutherland W, Williams S, Ball M. Dietary management of patients with familial hypercholesterolemia treated with simvastatin. *Q J Med* 1992; **85**: 825–831.
12. Clifton PM, Noakes M, Nestel PJ. Gender and diet interactions with simvastatin treatment. *Atherosclerosis* 1994; **110**: 25–33.
13. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RMC. Long term persistence with statin treatment in daily medical practice. *Heart* 2004; **90**: 1065–1066.
14. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA* 2002; **288**: 455–461.
15. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. *JAMA* 2002; **288**: 462–467.
16. Nagashima H, Kasanuki H. The status of lipid management in 1,836 patients with coronary artery disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. *J Atheroscler Thromb* 2005; **12**: 338–342.
17. Saito Y. JAS Guideline and statin treatment. *J Atheroscler Thromb* 2005; **12**: 343.



ELSEVIER

available at www.sciencedirect.com



journal homepage: www.elsevier.com/locate/diabres



International Diabetes Federation

Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus

Kyoko Tanimura^a, Yasushi Nakajima^a, Mototugu Nagao^a, Akira Ishizaki^a, Toshiko Kano^a, Taro Harada^a, Fumitaka Okajima^a, Mariko Sudo^a, Hideki Tamura^a, Shinya Ishii^a, Hitoshi Sugihara^a, Shizuya Yamashita^b, Akira Asai^a, Shinichi Oikawa^{a,*}

^a Department of Medicine, Division of Endocrinology and Metabolism, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo 113-8603, Japan

^b Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

ARTICLE INFO

Article history:

Received 29 December 2007

Received in revised form

17 March 2008

Accepted 24 April 2008

Published on line 16 July 2008

Keywords:

Apolipoprotein B48

ELISA

Type 2 diabetes mellitus

Diurnal change

Carotid plaque

ABSTRACT

Aims: The atherogenicity of chylomicron remnants has been discussed. We examined whether serum apoB48 level is associated with the presence of carotid plaque in type 2 diabetic patients.

Method: Forty type 2 diabetic patients (21 males and 19 females, 52.8 ± 11.8 years old; mean \pm S.D.) were divided into two groups by the presence or absence of carotid plaque. The diurnal change of serum apoB48 level was measured by enzyme-linked immunosorbent assay.

Results: Fasting serum apoB48 level was higher in the subjects with carotid plaque than those without (6.5 ± 3.8 vs. 4.1 ± 1.9 $\mu\text{g/ml}$, $p = 0.01$). Age- and gender-adjusted analysis showed that the presence of carotid plaque was associated with fasting apoB48 (OR 1.43; 95% CI, 1.07–2.09, $p = 0.04$) and triglyceride (OR 1.14; 95% CI, 1.02–1.32, $p = 0.04$) levels. In normal LDL-cholesterol (<140 mg/dl) subjects, the presence of carotid plaque was associated with fasting apoB48 level (OR 2.16; 95% CI, 1.22–5.32, $p = 0.04$), but not associated with fasting triglyceride level (OR 1.11; 95% CI, 0.99–1.30, $p = 0.13$).

Conclusions: Serum apoB48 level was strongly associated with the presence of carotid plaque in type 2 diabetic patients.

© 2008 Published by Elsevier Ireland Ltd.

1. Introduction

Dyslipidemia is related to the pathogenesis of atherosclerosis. The relationship between cardiovascular disease (CVD) and hypercholesterolemia, increased low-density lipoprotein cholesterol (LDL-C) level, or decreased high-density lipoprotein cholesterol (HDL-C), has been well documented. In contrast, the association between CVD and abnormality in triglyceride (TG) metabolism is still debated. Several prospective studies have shown positive association between serum TG level and

CVD [1–3]; however, other studies have demonstrated that TG level was no longer associated with atherosclerosis after adjustment for HDL-C [4,5]. The heterogeneity of TG-rich lipoproteins (i.e., chylomicron, VLDL, and those remnant lipoproteins) would make it difficult to evaluate the atherogenicity of hypertriglyceridemia. Recently, it was reported that elevated nonfasting TG level was associated with increased risk of cardiovascular events [6]. It suggests an association between increased remnant lipoproteins and increased risk of CHD. However, it has not been clinically

* Corresponding author. Tel.: +81 3 5802 8153; fax: +81 3 5802 8153.
0168-8227/\$ – see front matter © 2008 Published by Elsevier Ireland Ltd.
doi:10.1016/j.diabres.2008.04.028

established which TG-rich lipoproteins play a crucial role in atherosclerosis.

Chylomicron and its remnant have a characteristic apolipoprotein, apolipoprotein B48 (apoB48), each having one apoB48 molecule per particle. Hence, apoB48 could be a good marker for TG-rich lipoproteins derived from intestine. Several clinical studies indicated that apoB48 level was associated with atherosclerosis [7–10], but the association was not confirmed in other studies [11,12]. The inconsistent results may be due in part to differences in assay method for apoB48. To date, apoB48 level has been commonly evaluated by SDS-PAGE. However, the apoB48 value based on SDS-PAGE is essentially semi-quantitative [13]. Recently, an enzyme-linked immunosorbent assay (ELISA) method for apoB48 was newly established [14,15]. The ELISA method is simple and quantitative, and it has been used in some clinical studies [10,14].

Type 2 diabetes mellitus (DM) is one of the important risk factors for CVD. The mortality and morbidity of diabetic patients are markedly high compared to non-diabetic subjects [16]. In diabetic patients, dyslipidemia is recognized as an important CVD risk factor. A characteristic pattern of dyslipidemia in DM is high TG, low HDL-C, elevated small dense LDL-C, and postprandial lipemia. In type 2 DM, the production and clearance of TG-rich lipoproteins are disturbed [17]. Previous studies in type 2 DM demonstrated that apoB48 level was elevated [18], and apoB48-containing lipoproteins were increased in production and decreased in clearance [19]. Therefore, serum apoB48 level is expected to be increased throughout the day in type 2 DM; however, at present, little is known about the diurnal change. Furthermore, it remains uncertain whether serum apoB48 level is associated with atherosclerosis in type 2 DM. In the present study, we examined the diurnal change of serum apoB48 level and its association with atherosclerosis in type 2 DM.

2. Subjects and methods

2.1. Subjects

Basal data of 147 type 2 diabetic patients admitted to Nippon Medical School Hospital (Tokyo, Japan) for glycemic control were checked. Among these patients, 107 were excluded for the following reasons: treatment with steroid or lipid lowering drugs, complication with diabetic proliferative retinopathy or macroalbuminuria (>300 mg/day), primary hyperlipidemia, liver diseases, chronic renal diseases (>1.2 mg/dl of serum creatinine), infection, malignancy, endocrine diseases, recent major surgery or illness. After receipt of informed consent, 40 patients [21 males, 19 females; age 30–72 years (52.8 ± 11.8 , mean \pm S.D.)] were enrolled as the subjects of the present study. The subjects were divided into two groups by the presence or absence of carotid plaque (plaque (+) or (-), respectively). Standard lifestyle modifications (exercise and dietary changes) had been adopted for each subject before admission. Six subjects were treated with insulin (14.3% and 15.8% in plaque (+) and (-), respectively, $p = 0.89$) and 20 were treated with oral agents for diabetes (42.9% and 57.9%, $p = 0.34$), including sulphonylurea, glimepiride, metformin,

thiazolidinedione, and alpha-glucosidase inhibitor. Fifteen subjects did not take any medication for diabetes (42.9% and 26.3%, $p = 0.30$). There was no bias in treatment for diabetes between the two groups. This study was approved by the Nippon Medical School Hospital Ethics Committee.

2.2. Blood specimen preparation

The study-related assessments were performed within 10 days after admission. All subjects were assessed after an overnight fast of 14 h. The total calories of daily diet (kcal/day) were calculated as $27.5 \text{ (kcal)} \times \text{ideal body weight (IBW)}$. IBW (kg) was calculated as $22 \times [\text{height (m)}]^2$ according to the recommendation of the Japan Society for the Study of Obesity. The nutritional composition of daily diet was 20% fat, 25% protein, and 55% carbohydrate. Each subject was provided three meals per day, at 8:00, 12:00, and 18:00. To assess the diurnal changes in serum apoB48, serum lipids, and plasma glucose (PG), blood specimens were obtained at 30 min before and 2 h after each meal (7:30, 10:00, 11:30, 14:00, 17:30, and 20:00), night (23:00), and early morning (3:00). Blood was drawn from the cubital vein and collected in test tubes. The blood samples collected from 7:30 to 14:00 were immediately centrifuged, and the samples from 17:00 to 3:00 were kept at 4 °C and centrifuged the next morning. To analyze PG, a portion of each blood sample was collected into a tube with NaF and anticoagulant, and centrifuged immediately after blood collection. Serum and plasma were immediately collected after the centrifugations, and stored at -80 °C until assayed.

2.3. Clinical and biochemical assessment

Subjects underwent a physical examination (height, weight, blood pressure, and waist circumference). Blood pressure was measured with a standard mercury sphygmomanometer in a sitting position in the morning. Smoking habits, a familial history of CVD, and duration of DM were assessed by interview. Smoking was defined as current or past smoking. Serum total cholesterol (TC), HDL-C, and TG were measured by enzymatic methods (LABOSPECT 008, Hitachi, Tokyo, Japan). Glycated albumin (GA) was also measured enzymatically (JCA-BM12, Japan Electron Optics Laboratory, Tokyo, Japan). LDL-C level was calculated by the Friedewald formula [20]. Plasma glucose (PG) was measured by a glucose oxidase method (ADAMS Glucose GA-1170, Arkray, Kyoto, Japan), and hemoglobin A_{1c} (HbA_{1c}) was measured by high performance liquid chromatography (ADAMS A1c HA-8160, Arkray). The plasma levels of lipoprotein lipase mass and adiponectin were measured by ELISA (Daiichi Pure Chemicals and Otsuka pharmaceutical, Tokyo, Japan, respectively). Serum apoB48 level was measured by ELISA using an anti-human apoB48 monoclonal antibody (B-48-151) as previously described (Fujirebio, Tokyo, Japan) [14,15]. The apoB48 assay was highly reproducible, with coefficients of variation of 1.9–3.1% and 2.2–4.4% for intra- and inter-assay, respectively.

Carotid artery status was examined by high-resolution B-mode ultrasonography (SDU-2000, Shimadzu, Kyoto, Japan; iU22 and EnVisor, Philips Medical Systems, Andover, MA, USA; LOGIQ 7, GE Healthcare, Tokyo, Japan). The ultrasound devices

were used with electrical linear transducers (3–12 MHz). Subjects were placed in a supine position with the neck hyper-extended. Carotid plaque was assessed in common carotid artery, the carotid artery bifurcation, and internal carotid artery bilaterally. Plaque was defined as a localized intima-media thickness (IMT) ≥ 1.0 mm with marked protrusion. All measurements were performed by well-trained doctors.

2.5. Statistical analysis

Values are presented as means \pm S.D. Statistical analysis was performed by χ^2 test or Fisher's exact test, as appropriate, and Student's *t*-test or Welch's *t*-test, as appropriate. Logistic regression analysis was used to calculate odds ratios of each variable for carotid plaque. Because TG values were highly dispersed, the value TG/10 was used for the calculation of odds ratio. Data were analyzed with JMP 6 software (SAS Institute, Cary, NC). All statistical tests were two-sided, and $p < 0.05$ were considered significant.

3. Results

3.1. Clinical and laboratory data

The clinical and laboratory data of all subjects are presented in Table 1. There were no differences in gender distribution, age, duration of DM, smoking habit, body mass index, or blood pressure between the plaque (+) and (-) groups. The two groups were similar in fasting TC, LDL-C, PG, and HbA_{1c} levels. The fasting serum apoB48 and TG levels were significantly higher in plaque (+) than in plaque (-).

3.2. Diurnal changes in apoB48, lipids, and glucose

Diurnal changes in serum apoB48 and TG levels are shown in Fig. 1A and B. Serum apoB48 level was sharply increased after breakfast and reached peaks after lunch and dinner, then returned toward the fasting levels at 3:00 in both plaque (+) and plaque (-). ApoB48 and TG levels were significantly higher in plaque (+) than in plaque (-) throughout the day, with the exception of a few time points. PG level was elevated after each meal in a similar pattern for both groups (Supplementary Fig. 1A). The diurnal fluctuation of TC and HDL-C levels was small and similar in both groups (Supplementary Fig. 1B and C).

3.3. Association of apoB48 with plaque

The results of logistic regression analysis showed that fasting serum apoB48 and TG levels were significantly associated with the presence of carotid plaque, regardless of adjustment for age and gender (Table 2). Other variables were not associated with the presence of carotid plaque.

3.4. Analyses of subjects with normal LDL-C level (<140 mg/dl)

To exclude the involvement of LDL-C level on the association between apoB48 and carotid plaque, we examined this factor in normal LDL-C (<140 mg/dl) subjects ($n = 25$). The normal LDL-C level of <140 mg/dl was defined according to the recommendation of Japan Atherosclerosis Society [21]. Among the normal LDL-C subjects, 12 subjects were with carotid plaque [plaque (+)] and 13 were without the plaque [plaque (-)].

Table 1 – Clinical and laboratory data for all subjects

	Total (n = 40)	Plaque (+) (n = 21)	Plaque (-) (n = 19)	p value (+) vs. (-)
Male/female	21/19	13/8	8/11	0.21
Age (year)	52.8 \pm 11.8	53.4 \pm 9.9	52.1 \pm 13.9	0.72
Duration of DM (year)	5.9 \pm 6.3	5.9 \pm 7.0	5.9 \pm 5.7	0.99
Familial history of CVD (%)	10.0	14.3	5.3	0.37
Smoking (%)	57.5	66.7	47.4	0.22
BMI (kg/m ²)	24.1 \pm 3.9	23.9 \pm 3.1	24.4 \pm 4.7	0.68
Waist circumference (cm)	83.8 \pm 12.8	82.5 \pm 13.3	85.5 \pm 12.5	0.48
Blood pressure (mmHg)				
Systolic	121 \pm 12	122 \pm 11	120 \pm 13	0.59
Diastolic	73 \pm 10	73 \pm 9	73 \pm 11	0.80
TC (mg/dl)	210 \pm 43	217 \pm 38	201 \pm 47	0.23
HDL-C (mg/dl)	52 \pm 17	49 \pm 14	55 \pm 19	0.21
LDL-C (mg/dl)	130 \pm 32	136 \pm 30	123 \pm 32	0.19
TG (mg/dl)	140 \pm 73	163 \pm 84	115 \pm 48	0.03
Glucose (mg/dl)	177 \pm 59	181 \pm 67	172 \pm 50	0.64
HbA _{1c} (%)	9.8 \pm 2.1	10.1 \pm 2.2	9.5 \pm 1.9	0.40
GA (%)	28.0 \pm 19.1	27.8 \pm 8.5	28.1 \pm 10.0	0.92
Adiponectin (μ g/ml)	7.1 \pm 4.4	6.3 \pm 3.8	8.0 \pm 4.9	0.25
LPL (ng/ml)	35.9 \pm 14.4	34.4 \pm 13.2	37.7 \pm 15.7	0.49
ApoB48 (μ g/ml)	5.4 \pm 3.3	6.5 \pm 3.8	4.1 \pm 1.9	0.01

Values are means \pm S.D. Plaque (+), subjects with carotid plaque; plaque (-), subjects without carotid plaque; DM, diabetes mellitus; CVD, cardiovascular disease; BMI, body mass index; TC, total cholesterol; HDL-C, HDL cholesterol; TG, triglyceride; LDL-C, LDL cholesterol; HbA_{1c}, hemoglobin A_{1c}; GA, glycated albumin; LPL, lipoprotein lipase; apoB48, apolipoprotein B48.




Fig. 1 – Diurnal changes of serum apolipoprotein B48 (apoB48, A and C) and triglyceride (TG, B and D) levels in the subjects with (■) and without (□) carotid plaque. A and B, all subjects (19 and 21 subjects with and without carotid plaque, respectively). C and D, normal LDL-cholesterol (LDL-C < 140 mg/dl) subjects (13 and 12 subjects with and without carotid plaque, respectively). Values are means \pm SD. * p < 0.05 vs. subjects without plaque. Arrows indicate breakfast, lunch, and dinner at 8:00, 12:00, and 18:00, respectively.

In the normal LDL-C subjects, fasting apoB48 level was significantly higher in plaque (+) than in plaque (-); however, the fasting TG level and other parameters were not different between the two groups (Table 3). The diurnal pattern of apoB48 level in the normal LDL-C subjects (Fig. 1C) was similar to that in all subjects (Fig. 1A). ApoB48 level was significantly higher in plaque (+) than in plaque (-) throughout the day,

with the exception of a few time points (Fig. 1C). In contrast, TG level was not significantly different between the two groups, except at 3:00 (Fig. 1D). The diurnal changes of PG, TC, and HDL-C are similar in both plaque (+) and (-) (data not shown). Table 4 shows the results of logistic regression analysis in the normal LDL-C subjects. Regardless of gender and age adjustment, the fasting apoB48 level was significantly

Table 2 – Unadjusted, and age- and gender-adjusted odds ratios for the presence of carotid plaque in all subjects ($n = 40$)

Variable	Unadjusted		Adjusted	
	Odds ratio (95% CI)	p value	Odds ratio (95% CI)	p value
Age	1.01 (0.96–1.07)	0.71		
Gender (male)	1.50 (0.80–2.87)	0.21		
Smoking	1.49 (0.79–2.88)	0.22	1.33 (0.63–2.82)	0.45
HDL-C	0.97 (0.93–1.01)	0.21	0.98 (0.92–1.02)	0.34
LDL-C	1.01 (0.99–1.04)	0.19	1.02 (0.10–1.05)	0.12
TG	1.13 (1.02–1.28)	0.04	1.14 (1.02–1.32)	0.04
HbA _{1c}	1.15 (0.84–1.60)	0.39	1.16 (0.84–1.66)	0.39
ApoB48	1.42 (1.08–2.03)	0.03	1.43 (1.07–2.09)	0.04

CI, confidence interval; HbA_{1c}, hemoglobin A_{1c}; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; ApoB48, apolipoprotein B48.

Table 3 - Clinical and laboratory data in normal LDL-C (<140 mg/dl) subjects

	Total (n = 25)	Plaque (+) (n = 12)	Plaque (-) (n = 13)	p value (+) vs. (-)
Male/female	14/11	7/5	7/6	0.82
Age (year)	51.1 ± 12.5	50.0 ± 3.7	52.0 ± 3.5	0.71
Duration of DM (year)	4.8 ± 5.3	3.7 ± 1.5	5.8 ± 1.5	0.32
Familial history of CVD (%)	8.0	8.3	7.6	0.43
Smoking (%)	60.0	66.7	53.8	0.76
BMI (kg/m ²)	24.0 ± 3.4	23.5 ± 1.0	24.5 ± 3.7	0.50
Waist circumference (cm)	83.2 ± 13.3	79.5 ± 3.8	86.9 ± 3.8	0.18
Blood pressure (mmHg)				
Systolic	120 ± 13	122 ± 4	118 ± 4	0.37
Diastolic	71 ± 11	71 ± 11	71 ± 12	0.89
TC (mg/dl)	189 ± 34	199 ± 31	179 ± 35	0.15
HDL-C (mg/dl)	49 ± 14	49 ± 14	49 ± 14	0.89
LDL-C (mg/dl)	111 ± 22	116 ± 6	107 ± 6	0.32
TG (mg/dl)	140 ± 83	169 ± 23	113 ± 22	0.09
Glucose (mg/dl)	183 ± 65	196 ± 72	172 ± 59	0.37
HbA _{1c} (%)	9.7 ± 2.1	10.0 ± 0.6	9.3 ± 0.6	0.45
GA (%)	28.0 ± 9.9	28.1 ± 2.9	27.9 ± 2.8	0.96
Adiponectin (µg/ml)	6.9 ± 4.3	6.5 ± 1.3	7.3 ± 1.2	0.61
LPL (ng/ml)	35.9 ± 15.0	37.1 ± 4.6	34.8 ± 4.4	0.73
ApoB48 (µg/ml)	4.8 ± 3.6	6.5 ± 4.4	3.2 ± 1.5	0.03

Values are means ± S.D. Plaque (+), subjects with carotid plaque; plaque (-), subjects without carotid plaque; DM, diabetes mellitus; CVD, cardiovascular disease; BMI, body mass index; TC, total cholesterol; HDL-C, HDL cholesterol; TG, triglyceride; LDL-C, LDL cholesterol; HbA_{1c}, hemoglobin A_{1c}; GA, glycated albumin; LPL, lipoprotein lipase; apoB48, apolipoprotein B48.

associated with the presence of carotid plaque. The fasting TG level and other variables were not associated with the presence of carotid plaque.

4. Discussion

The present study demonstrated that fasting serum apoB48 level was associated with the presence of carotid plaque in type 2 DM and that diurnal apoB48 level was significantly higher in the plaque (+) group than in the plaque (-) group, throughout most of the day. The present result that apoB48 is associated with atherosclerosis is consistent with several previous studies [7-10]. To date, possible underlying mechanisms for the association have been suggested in several in vitro experiments. Flood et al. [22] indicated that apoB48 possesses a binding site to arterial wall proteoglycans, and the interaction will induce the retention of apoB48-containing lipopro-

teins. It is also reported that chylomicron remnants were taken up by macrophages via LDL receptor-related protein [23] and apoB48 receptor [24,25]. These results suggest that apoB48-containing lipoproteins could penetrate into vascular subendothelial space, and where it could be involved in macrophage foam cell formation. In fact, apoB48-containing lipoproteins penetrated into the artery wall and were retained within the subendothelial space of the carotid artery in Watanabe heritable hyperlipidemic rabbits [26]. Furthermore, ApoB48 was also identified in human atherosclerotic plaque [27].

It is well established that high LDL-C level is a strong determinant of atherosclerosis; however, high LDL-C level was not significantly associated with the presence of carotid plaque in the present study. This result might be due to the range and the mean value of LDL-C in the subjects. In the present study, the range was not particularly wide and the mean value was not high (130 ± 32 mg/dl), which might be the

Table 4 - Unadjusted, and age- and gender-adjusted odds ratios for the presence of carotid plaque in normal LDL-cholesterol (<140 mg/dl) subjects (n = 25)

Variable	Unadjusted		Adjusted	
	Odds ratio (95% CI)	p value	Odds ratio (95% CI)	p value
Age	0.99 (0.92-1.05)	0.70		
Gender (male)	1.10 (0.49-2.46)	0.82		
Smoking	1.31 (0.59-3.04)	0.51	1.38 (0.50-4.21)	0.54
HDL-C	1.00 (0.94-1.06)	0.88	1.00 (0.93-1.08)	0.90
LDL-C	1.02 (0.98-1.07)	0.31	1.03 (0.99-1.08)	0.21
TG	1.11 (0.99-1.29)	0.11	1.11 (0.99-1.30)	0.13
HbA _{1c}	1.17 (0.80-1.73)	0.43	1.17 (0.80-1.78)	0.43
ApoB48	1.91 (1.17-4.03)	0.04	2.16 (1.22-5.32)	0.04

CI, confidence interval; HbA_{1c}, hemoglobin A_{1c}; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; ApoB48, apolipoprotein B48.

reason that significance was not observed in the association of LDL-C with carotid plaque. The present study indicated that apoB48 level was strongly associated with carotid plaque. Even when LDL-C was within the normal range, an elevated apoB48 level would be a risk factor for atherosclerosis in type 2 DM.

In general, age, hypertension, history of smoking, and low HDL-C predict carotid atherosclerosis. However, these factors were not associated with the presence of carotid plaque in this study. The lack of association may be due to the characteristics and small number of the subjects. In our study, the proportion of age ≤ 45 years was 20%. This small proportion of young subjects may not have a statistical power, because carotid plaque area was reported to be strongly related to age, increased between 45 and 70 years of age markedly, and measurable plaque were more detected in >45 -year subjects [28]. With respect to blood pressure, most of our subjects had normal blood pressure (the proportions of systolic blood pressure <135 mmHg and diastolic blood pressure <85 mmHg were 85% and 88%, respectively). Low HDL-C (<40 mg/dl) subjects were 20% in our study. These biases of the subjects may be the reason why the conventional atherosclerotic risk factors did not associated with the presence of carotid plaque in the present study. The lack of association between smoking habit and carotid plaque might be because we defined smoking as both current and past smoking, and did not account daily cigarette consumption.

ApoB48-containing lipoproteins were reported to be increased in production and decreased in clearance in type 2 DM [19], but little is known about its diurnal profile. The present study showed that the diurnal level of apoB48 fluctuated more than that of TG in type 2 DM, and was higher in plaque (+) than in plaque (-) throughout the day. The diurnal profile of apoB48 level would reflect the metabolism of chylomicron and its remnants, and high level of fasting apoB48 would indicate the accumulation of chylomicron remnants. These results suggest that apoB48 is more useful as a maker for atherogenic lipoprotein abnormality than TG. Campos et al. [29] reported the diurnal change in apoB48 level in normolipidemic subjects, indicating that the apoB48 level in both light and dense VLDL fraction were increased sharply after breakfast, increased slightly after lunch, and not increased immediately after dinner. In contrast, in the present study, serum apoB48 level was sharply increased after each meal. One reason for the inconsistent results may be the difference in the assay method for apoB48. Campos et al. evaluated apoB48 level in each lipoprotein fraction by SDS-PAGE, whereas we evaluated that in serum by ELISA. In addition, the difference in the subjects (normolipidemia vs. type 2 DM) might affect the discordance in the diurnal apoB48 profiles.

In conclusion, serum apoB48 level was strongly associated with the presence of carotid plaque in type 2 DM and was higher in the subjects with carotid plaque than in the subjects without the plaque throughout the day. The measurement of serum apoB48 may be useful to evaluate the risk of atherosclerosis. The present results warrant further studies, in large scale and prospective design, to confirm the significance of the measurement of apoB48.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.diabres.2008.04.028.

5. Conflict of interest

The authors declare that they have no conflict of interest.

REFERENCES

- [1] J.E. Hokanson, M.A. Austin, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, *J. Cardiovasc. Risk* 3 (1996) 213–219.
- [2] N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, et al., Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies, *Circulation* 115 (2007) 450–458.
- [3] H. Iso, Y. Naito, S. Sato, A. Kitamura, T. Okamura, T. Sankai, et al., Serum triglycerides and risk of coronary heart disease among Japanese men and women, *Am. J. Epidemiol.* 153 (2001) 490–499.
- [4] M.H. Criqui, G. Heiss, R. Cohn, L.D. Cowan, C.M. Suchindran, S. Bangdiwala, et al., Plasma triglyceride level and mortality from coronary heart disease, *N. Engl. J. Med.* 328 (1993) 1220–1225.
- [5] L. Wilhelmsen, H. Wedel, G. Tibblin, Multivariate analysis of risk factors for coronary heart disease, *Circulation* 48 (1973) 950–958.
- [6] B.G. Nordestgaard, M. Benn, P. Schnohr, A. Tybjaerg-Hansen, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, *JAMA* 298 (2007) 299–308.
- [7] N. Mero, R. Malmström, G. Steiner, M.R. Taskinen, M. Syväne, Postprandial metabolism of apolipoprotein B-48 and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease, *Atherosclerosis* 150 (2000) 167–177.
- [8] E. Meyer, H.T. Westerveld, F.C. de Ruyter Meijstek, M.M. van Greevenbroek, R. Rienks, H.J. van Rijn, et al., Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study, *Atherosclerosis* 124 (1996) 221–235.
- [9] F. Karpe, U. de Faire, M. Mercuri, M.G. Bond, M.L. Hellénus, A. Hamsten, Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men, *Atherosclerosis* 141 (1998) 307–314.
- [10] N. Sakai, T. Sugimoto, K. Tsujii, H. Hiraoka, T. Nakamura, S. Yamashita, et al., Fasting serum apolipoprotein (apo) B-48 levels measured by a novel ELISA are a simple and useful marker for postprandial hyperlipidemia and predict coronary heart disease (CHD), *Circulation* 110 (Suppl. III) (2004), III-183.
- [11] S. Boquist, G. Ruotolo, R. Tang, J. Björkegren, M.G. Bond, U. de Faire, et al., Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men, *Circulation* 100 (1999) 723–728.

- [12] R. Valero, A.M. Lorec, F. Paganelli, S. Beliard, C. Atlan, D. Lairon, et al., Fasting apolipoprotein B-48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia, *Metabolism* 54 (2005) 1442–1447.
- [13] K.G. Jackson, C.M. Williams, Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA, *Atherosclerosis* 176 (2004) 207–217.
- [14] N. Sakai, Y. Uchida, K. Ohashi, T. Hibuse, Y. Saika, Y. Tomari, et al., Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA, *J. Lipid Res.* 44 (2003) 1256–1262.
- [15] Y. Uchida, Y. Kurano, S. Ito, Establishment of monoclonal antibody against human Apo B-48 and measurement of ApoB-48 in serum by ELISA method, *J. Clin. Lab. Anal.* 12 (1998) 289–292.
- [16] S.M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, *N. Engl. J. Med.* 339 (1998) 229–234.
- [17] M.R. Taskinen, Diabetic dyslipidaemia: from basic research to clinical practice, *Diabetologia* 46 (2003) 733–749.
- [18] A. Curtin, P. Deegan, D. Owens, P. Collins, A. Johnson, G.H. Tomkin, Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48, *Acta Diabetol.* 33 (1996) 205–210.
- [19] J.C. Hogue, B. Lamarche, A.J. Tremblay, J. Bergeron, C. Gagné, P. Couture, Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes, *J. Lipid Res.* 48 (2007) 1336–1342.
- [20] W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, *Clin. Chem.* 18 (1972) 499–502.
- [21] T. Teramoto, J. Sasaki, H. Ueshima, G. Egusa, M. Kinoshita, K. Shimamoto, et al., Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for Dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular disease for Japanese, *J. Atheroscler. Thromb.* 14 (2007) 155–158.
- [22] C. Flood, M. Gustafsson, P.E. Richardson, S.C. Harvey, J.P. Segrest, J. Borén, Identification of the proteoglycan binding site in apolipoprotein B48, *J. Biol. Chem.* 277 (2002) 32228–32233.
- [23] Y. Fujioka, A.D. Cooper, L.G. Fong, Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages, *J. Lipid Res.* 39 (1998) 2339–2349.
- [24] M.L. Brown, M.P. Ramprasad, P.K. Umeda, A. Tanaka, Y. Kobayashi, T. Watanabe, et al., A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis, *Proc. Natl. Acad. Sci. U.S.A.* 97 (2000) 7488–7493.
- [25] A. Kawakami, M. Tani, T. Chiba, K. Yui, S. Shinozaki, K. Nakajima, et al., Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism, *Arterioscler. Thromb. Vasc. Biol.* 25 (2005) 424–429.
- [26] S.D. Proctor, J.C. Mamo, Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits, *Arterioscler. Thromb. Vasc. Biol.* 23 (2003) 1595–1600.
- [27] S. Pal, K. Semorine, G.F. Watts, J. Mamo, Identification of lipoproteins of intestinal origin in human atherosclerotic plaque, *Clin. Chem. Lab. Med.* 41 (2003) 792–795.
- [28] J.D. Spence, M. Eliasziw, M. DiCicco, D.G. Hackam, R. Galil, T. Lohmann, Carotid plaque area. A tool for targeting and evaluating vascular preventive therapy, *Stroke* 33 (2002) 2916–2922.
- [29] H. Campos, C. Khoo, F.M. Sacks, Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans, *Atherosclerosis* 181 (2005) 345–351.

INSIG2 gene rs7566605 polymorphism is associated with severe obesity in Japanese

Kikuko Hotta · Michihiro Nakamura · Yoshio Nakata · Tomoaki Matsuo · Seika Kamohara · Kazuaki Kotani · Ryoya Komatsu · Naoto Itoh · Ikuo Mineo · Jun Wada · Hiroaki Masuzaki · Masato Yoneda · Atsushi Nakajima · Shigeru Miyazaki · Katsuto Tokunaga · Manabu Kawamoto · Tohru Funahashi · Kazuyuki Hamaguchi · Kentaro Yamada · Toshiaki Hanafusa · Shinichi Oikawa · Hironobu Yoshimatsu · Kazuwa Nakao · Toshiie Sakata · Yuji Matsuzawa · Kiyoji Tanaka · Naoyuki Kamatani · Yusuke Nakamura

Received: 16 April 2008 / Accepted: 18 June 2008 / Published online: 10 July 2008
© The Japan Society of Human Genetics and Springer 2008

Abstract The single nucleotide polymorphism (SNP) rs7566605 in the upstream region of the insulin-induced gene 2 (*INSIG2*) is associated with the obesity phenotype in many Caucasian populations. In Japanese, this association with the obesity phenotype is not clear. To investigate the relationship between rs7566605 and obesity in Japanese, we genotyped rs7566605 from severely obese subjects [$n = 908$, body mass index (BMI) ≥ 30 kg/m²] and normal-

weight control subjects ($n = 1495$, BMI < 25 kg/m²). A case-control association analysis revealed that rs7566605 was significantly associated with obesity in Japanese. The *P* value in the minor allele recessive mode was 0.00020, and the odds ratio (OR) adjusted for gender and age was 1.61 [95% confidential interval (CI) = 1.24–2.09]. Obesity-associated phenotypes, which included the level of BMI, plasma glucose, hemoglobin A1c, total cholesterol,

K. Hotta (✉) · M. Nakamura
Laboratory for Endocrinology and Metabolism,
Center for Genomic Medicine, RIKEN, 1-7-22 Suehiro,
Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
e-mail: kikuko@src.riken.jp

Y. Nakata · T. Matsuo · K. Tanaka
Institute of Health and Sport Sciences, University of Tsukuba,
Ibaraki, Japan

S. Kamohara
Medicine and Health Science Institute,
Tokyo Medical University, Tokyo, Japan

K. Kotani · T. Funahashi · Y. Matsuzawa
Department of Metabolic Medicine,
Graduate School of Medicine,
Osaka University, Osaka, Japan

R. Komatsu
Rinku General Medical Center, Osaka, Japan

N. Itoh
Toyonaka Municipal Hospital, Osaka, Japan

I. Mineo
Otemae Hospital, Osaka, Japan

J. Wada
Department of Medicine and Clinical Science,
Okayama University Graduate School of Medicine
and Dentistry, Okayama, Japan

H. Masuzaki · K. Nakao
Department of Medicine and Clinical Science,
Kyoto University Graduate School of Medicine, Kyoto, Japan

M. Yoneda · A. Nakajima
Division of Gastroenterology, Yokohama City University
Graduate School of Medicine, Kanagawa, Japan

S. Miyazaki
Tokyo Postal Services Agency Hospital, Tokyo, Japan

K. Tokunaga
Itami City Hospital, Hyogo, Japan

M. Kawamoto · N. Kamatani
Institute of Rheumatology, Tokyo Women's Medical University,
Tokyo, Japan

K. Hamaguchi
Department of Community Health and Gerontological Nursing,
Faculty of Medicine, Oita University, Oita, Japan

K. Yamada
Department of Medicine, Division of Endocrinology
and Metabolism, Kurume University, Fukuoka, Japan

T. Hanafusa
First Department of Internal Medicine,
Osaka Medical College, Osaka, Japan

triglycerides, high-density lipoprotein (HDL) cholesterol, and blood pressure, were not associated with the rs7566605 genotype. Thus, rs7566605 in the upstream region of the *INSIG2* gene was found to be associated with obesity, i.e., severe obesity, in Japanese.

Keywords Insulin-induced gene 2 · Obesity · Japanese population · Association · SNP

Introduction

Obesity has become one of the major issues in public health, medicine, and the economy (Kopelman 2000). Obesity is considered to be important due to its relationship with various complications, such as diabetes mellitus, dyslipidemia, and hypertension. A combination of these dysfunctions is now defined as the metabolic syndrome that significantly increases the risk of cardiovascular disease (Wilson and Grundy 2003). Genetic and environmental factors contribute to the development of obesity (Maes et al. 1997; Barsh et al. 2000; Rankinen et al. 2006). Due to the recent progress in single nucleotide polymorphism (SNP) genotyping techniques, it is possible to conduct genome-wide screens to identify common genetic variants associated with obesity. We conducted a large-scale case-control association study and found that secretogranin III (*SCG3*) (Tanabe et al. 2007) and myotubularin-related protein 9 (*MTMR9*) (Yanagiya et al. 2007) confer susceptibility to the obesity phenotype in the Japanese population. Genome-wide association studies have shown that variations in the upstream region of the insulin-induced gene 2 (*INSIG2*) (Herbert et al. 2006) and in the fat-mass and obesity-associated gene (*FTO*) (Frayling et al. 2007; Scuteri et al. 2007; Hinney et al. 2007) are associated with the obesity phenotype. We recently reported the association between variations in the *FTO* gene and severe obesity in Japanese (Hotta et al. 2008). An association between

rs7566605 in the upstream region of the *INSIG2* gene and obesity was also found in several Caucasian and Hispanic American populations (Herbert et al. 2006; Hall et al. 2006; Lyon et al. 2007; Liu et al. 2008). However, results from some reports with respect to these associations could not be reproduced (Lyon et al. 2007; Smith et al. 2007; Boes et al. 2008); further, these associations are not observed in the Indian (Kumar et al. 2007), Chinese (Yang et al. 2008) and Japanese populations (Tabara et al. 2008). Thus, the association between rs7566605 in the *INSIG2* gene and obesity in Japanese remains controversial.

To investigate the relationship between the *INSIG2* gene and obesity in Japanese, we performed a case-control association study involving patients with severe adult obesity (BMI ≥ 30 kg/m²) and normal weight controls (BMI < 25 kg/m²). We found that rs7566605 was significantly associated with severe adult obesity.

Materials and methods

Study subjects

Severely obese subjects were recruited from among the outpatients of medical institutes. Patients with secondary obesity and obesity-related hereditary disorders were excluded from this study, as were patients with medication-induced obesity. Control subjects were recruited from among subjects who had undergone a medical examination for the screening of common diseases. Each subject provided written informed consent, and the protocol was approved by the ethics committee of each institution and that of RIKEN. The sample size for the severely obese subjects (BMI ≥ 30 kg/m²) was 908 (male:female ratio, 418:590; age, 49.1 \pm 14.2 years; BMI, 34.5 \pm 5.4 kg/m²), whereas that for the normal weight controls (BMI < 25 kg/m²) was 1,495 (male:female ratio, 672:823; age, 48.1 \pm 16.5 years; BMI, 21.6 \pm 2.1 kg/m²). Subjects' clinical features are illustrated in Table 1.

DNA preparation and SNP genotyping

Genomic DNA was prepared from the blood samples of each subject with a Genomix kit (Talent Srl, Trieste, Italy). SNP rs7566605 reported in a previous genome-wide association study (Herbert et al. 2006) was genotyped with TaqMan probe (C_29404113_20; Applied Biosystems; Foster City, CA, USA).

Statistical analysis

Genotype or allele frequencies were compared between cases and controls in three different modes. In the first

S. Oikawa
Department of Medicine, Division of Endocrinology
and Metabolism, Nippon Medical School, Tokyo, Japan

H. Yoshimatsu · T. Sakata
Department of Anatomy, Biology and Medicine,
Faculty of Medicine, Oita University, Oita, Japan

N. Kamatani
Laboratory for Statistical Analysis, Center for Genomic
Medicine, RIKEN, Tokyo, Japan

Y. Nakamura
Laboratory for Molecular Medicine, Human Genome Center,
The Institute of Medical Science, University of Tokyo,
Tokyo, Japan

Table 1 Clinical characterization of obese and control subjects

	Obese	Control	<i>P</i> value ^a
Sample size	908	1495	–
Gender (M/F)	418/490	672/823	–
Age (year)	49.1 ± 14.2	48.1 ± 16.5	0.050
BMI (kg/m ²)	34.50 ± 5.39	21.65 ± 2.07	<0.000001
Glucose (mg/dl)	129.1 ± 49.7	97.7 ± 23.8	<0.000001
HbA1c (%)	6.5 ± 1.8	5.1 ± 0.6	<0.000001
Total cholesterol (mg/dl)	210.1 ± 38.0	201.2 ± 36.4	<0.000001
Triglycerides (mg/dl)	155.6 ± 111.0	104.0 ± 73.1	<0.000001
HDL cholesterol (mg/dl)	53.1 ± 18.8	65.1 ± 15.6	<0.000001
Systolic blood pressure (mmHg)	136.4 ± 18.2	123.4 ± 17.8	<0.000001
Diastolic blood pressure (mmHg)	83.8 ± 12.0	76.0 ± 11.1	<0.000001

Data are mean ± standard deviation

HbA1c hemoglobin A1c, HDL high-density lipoprotein

^a *P* values were analyzed using Mann–Whitney *U* test

mode, i.e., the allele frequency mode, allele frequencies were compared with a 2 × 2 contingency table. In the second mode, i.e., the minor allele recessive mode, frequencies of the homozygous genotype for the minor allele were compared with a 2 × 2 contingency table. In the third mode, i.e., the minor allele dominant mode, frequencies of the homozygous genotype for the major allele were compared with a 2 × 2 contingency table. A test of independence was performed using Pearson's χ^2 method. Odds ratio (OR) and 95% confidence interval (CI) were calculated by Woolf's method. The rs7566605 genotype was transformed to a multidichotomous variable, i.e., homozygosity with C alleles versus the other genotypes. The OR adjusted for age and gender was calculated by multiple logistic regression analysis, with genotype, age, and gender as independent variables. Hardy–Weinberg equilibrium was assessed using the χ^2 test (Nielsen et al. 1998). A simple comparison of clinical data among the different genotypes was performed by one-way analysis of variance (ANOVA). Statistical analyses were performed with StatView 5.0 (SAS Institute Inc., Cary, NC, USA).

Results

Case–control association study

We successfully genotyped rs7566605 by the TaqMan assay and performed tests of independence between the phenotype and genotype of obesity in severely obese subjects (BMI ≥ 30 kg/m²) and normal weight controls (BMI < 25 kg/m²). The minor allele frequency (MAF) of rs7566605 in the control group was 0.31. This was consistent with data obtained from the haplotype map of the human genome (HapMap). As shown in Table 2, rs7566605 demonstrated significant association with the obesity phenotype [recessive mode, *P* = 0.00020, and the OR (95% CI) was 1.62 (1.26–2.10)]. The rs7566605

genotype was transformed to a multidichotomous variable, i.e., CC homozygote versus the other genotypes. Multiple logistic regression analysis was performed, with genotype, age, and gender as independent variables. The *P* values for age, gender, and genotype were 0.21, 0.51, and 0.00030, respectively. OR (95% CI) was 1.61 (1.24–2.09). Our data indicated that rs7566605 in the *INSIG2* gene was associated with severe obesity in Japanese.

A deviation from the Hardy–Weinberg equilibrium was detected in cases (*P* = 0.0015), because this SNP is associated with obesity and cases were selected by phenotype. Cases were selected on the basis of BMI, and the prevalence of subjects with a BMI ≥ 30 kg/m² is only 2–3% in Japan (Yoshiike et al. 2002). Cases may be biased and not representative of the general population. Thus, it is not unexpected that cases were not in accordance with Hardy–Weinberg equilibrium.

Analysis of various quantitative phenotypes with rs7566605

To investigate whether the genotypes of SNP rs7566605 are associated with the phenotypes of metabolic disorders, we compared the following among the different genotypes in cases, controls, and combined groups: ANOVA results; BMI; levels of fasting plasma glucose; hemoglobin A1c (HbA1c); total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol; and blood pressure. Quantitative phenotypes with respect to BMI and levels of fasting plasma glucose; HbA1c; total cholesterol, triglycerides, and HDL cholesterol; and blood pressure were not found to be significantly associated with the rs7566605 genotypes in either cases or controls (Table 3). Systolic and diastolic blood pressures were significantly lower in the GG homozygote in the control group. Blood pressure was higher in GG homozygote in the obese group. Thus, the rs7566605 genotype was not associated with blood pressure.

Table 2 Association of rs7566605 in the *INSIG2* gene with severe obesity

Sample (sample size)	No. of subjects (%)			No. of chromosomes (%)		HWE test ^a		
	CC	CG	GG	C	G	χ^2	<i>P</i> value	
Case (<i>n</i> = 908)	127 (14)	365 (40)	416 (46)	619 (34)	1,197 (66)	10.1	0.0015	
Control (<i>n</i> = 1495)	136 (9)	664 (44)	695 (46)	936 (31)	2,054 (69)	1.6	0.21	
Allele frequency mode ^b		Minor allele recessive mode ^b			Minor allele dominant mode ^b			
χ^2	<i>P</i> value	OR ^c (95% CI)	χ^2	<i>P</i> value	OR ^c (95% CI)	χ^2	<i>P</i> value	OR ^c (95% CI)
4.0	0.046	1.13 (1.00–1.28)	13.9	0.00020	1.62 (1.26–2.10)	0.1	0.75	1.03 (0.87–1.21)

^a Hardy–Weinberg equilibrium test^b Association test was performed in three different modes as described in the “Materials and methods”, and the results in the three modes are shown^c Odds ratio (OR) with 95% confidence interval (CI)**Table 3** Comparison of various quantitative phenotypes among different genotypes at rs7566605 in obese and control subjects

	Obese ^a			Control ^a		
	CC (<i>n</i> = 127)	CG (<i>n</i> = 365)	GG (<i>n</i> = 416)	CC (<i>n</i> = 136)	CG (<i>n</i> = 664)	GG (<i>n</i> = 695)
Age (year)	48.5 ± 15.2	48.0 ± 14.0	50.0 ± 14.2	47.7 ± 17.4	48.1 ± 16.7	48.4 ± 16.4
<i>P</i> value ^b		0.13			0.89	
BMI (kg/m ²)	35.22 ± 6.91	34.28 ± 5.09	34.52 ± 5.21	21.70 ± 2.06	21.68 ± 2.07	21.60 ± 2.10
<i>P</i> value		0.25			0.73	
Glucose (mg/dl)	127.8 ± 44.1	129.3 ± 50.3	129.1 ± 50.8	102.0 ± 40.6	98.0 ± 21.7	97.0 ± 21.9
<i>P</i> value		0.96			0.23	
HbA1c (%)	6.4 ± 1.7	6.5 ± 1.8	6.5 ± 1.8	5.1 ± 0.8	5.1 ± 0.6	5.1 ± 0.6
<i>P</i> value		0.93			0.81	
Total cholesterol (mg/dl)	209.1 ± 39.3	209.3 ± 37.5	210.4 ± 38.1	204.1 ± 35.0	199.4 ± 36.9	202.2 ± 36.3
<i>P</i> value		0.90			0.23	
Triglycerides (mg/dl)	147.1 ± 85.4	160.1 ± 127.3	153.9 ± 102.7	99.6 ± 58.2	103.0 ± 65.5	105.6 ± 82.3
<i>P</i> value		0.51			0.62	
HDL cholesterol (mg/dl)	51.6 ± 14.1	52.7 ± 15.9	53.8 ± 22.2	67.3 ± 14.8	64.9 ± 15.8	65.0 ± 15.6
<i>P</i> value		0.52			0.45	
SBP ^c (mmHg)	134.8 ± 15.3	136.8 ± 18.7	136.6 ± 18.4	122.9 ± 15.8	125.4 ± 17.9	121.9 ± 18.0
<i>P</i> value		0.57			0.0019	
DBP ^d (mmHg)	82.9 ± 11.1	84.6 ± 11.7	83.4 ± 12.4	76.5 ± 11.3	77.0 ± 11.1	75.1 ± 11.1
<i>P</i> value		0.26			0.008	

Data are mean ± standard deviation

BMI body mass index, HbA1c hemoglobin A1c, HDL high-density lipoprotein

^a Data of each quantitative phenotype were compared among different genotypes at the rs7566605 in obese and control subjects^b *P* values were analyzed using analysis of variance in each group of obese and control subjects^c Systolic blood pressure^d Diastolic blood pressure

Discussion

Recent genome-wide association studies have shown that rs7566605 in the upstream region of the *INSIG2* gene is associated with obesity (Herbert et al. 2006). Associations between rs7566605 and the obesity phenotype have been observed in many Caucasian subjects (Herbert et al. 2006;

Hall et al. 2006; Lyon et al. 2007; Liu et al. 2008). However, these associations were controversial with regard to Asian subjects (Yang et al. 2008; Tabara et al. 2008). The association between rs7566605 and BMI may be hard to be replicated in the Asian general population due to the relatively smaller average BMI value and smaller proportion of obesity with BMI >30 kg/m² in Asians compared with

those in Caucasians. Indeed, criteria of obesity is BMI >30 kg/m² in Caucasians and BMI >25 kg/m² in Japanese. We could show the contribution of rs7566605 to obesity in Japanese using severely obese patients with a BMI ≥30 kg/m² as cases. SNP rs7566605 could also contribute to the development of severe obesity in Japanese.

Allele frequency was 0.31–0.34 in Japanese, just as observed in European subjects, and the CC genotype was also associated with severe obesity in Japanese, as previously reported (Herbert et al. 2006; Hall et al. 2006; Lyon et al. 2007; Liu et al. 2008). However, CC genotype was not significantly associated with BMI in obese and control groups, although CC homozygotes had higher BMI. Thus, it is possible that our study did not have sufficient power to detect the association between rs7566605 and BMI. The CC genotype would be thrifty variation and have an advantage for survival before modern times. Subjects with CC genotype would be susceptible to obesity in recent years. As a result, the number of CC homozygotes would increase in severely obese group, leading to a deviation from Hardy–Weinberg equilibrium.

Since rs7566605 exists approximately 10 kb upstream from *INSIG2*, SNPs may affect the transcriptional activity of *INSIG2*. *INSIG2* is expressed ubiquitously. It was downregulated by insulin in the liver and involved in fatty acid synthesis (Yabe et al. 2003; Takaishi et al. 2004). *INSIG2* also mediates feedback control of cholesterol synthesis (Goldstein et al. 2006). Although serum total cholesterol, HDL cholesterol, and triglycerides were not significantly different among genotypes, it is possible that *INSIG2* is related to obesity as it affects lipid metabolism.

In summary, our study indicated that rs7566605 in the upstream region of the *INSIG2* gene may influence the risk of severe obesity in Japanese.

Acknowledgments This work was supported by Takeda Science Foundation (KH).

References

- Barsh GS, Farooqi IS, O'Rahilly S (2000) Genetics of body-weight regulation. *Nature* 404:644–651
- Boes E, Kollerits B, Heid IM, Hunt SC, Pichler M, Paulweber B, Coassin S, Adams TD, Hopkins PN, Lingenhel A, Wagner SA, Kronenberg F (2008) *INSIG2* polymorphism is neither associated with BMI nor with phenotypes of lipoprotein metabolism. *Obesity* 16:827–833
- Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JRB, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJF, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CNA, Doney ASF, Morris AD, Smith GD, The Wellcome Trust Case Control Consortium, Hattersley AT, McCarthy MI (2007) A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 316:889–894
- Goldstein JL, DeBose-Boyd RA, Brown MS (2006) Protein sensors for membrane sterols. *Cell* 124:35–46
- Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeuffer A, Illig T, Wichmann HE, Meitinger T, Hunter D, Hu FB, Colditz G, Hinney A, Hebebrand J, Koberwitz K, Zhu X, Cooper R, Ardlie K, Lyon H, Hirschhorn JN, Laird NM, Lenburg ME, Lange C, Christman MF (2006) A common genetic variant is associated with adult and childhood obesity. *Science* 312:279–283
- Hall DH, Rahman T, Avery PJ, Keavney B (2006) *INSIG2* promoter polymorphism and obesity related phenotypes: association study in 1428 members of 248 families. *BMC Med Genet* 7:83–88
- Hinney A, Nguyen TT, Scherag A, Friedel S, Bröner G, Müller TD, Grallert H, Illig T, Wichmann HE, Rief W, Schäfer H, Hebebrand J (2007) Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (*FTO*) variants. *PLoS ONE* 2:1361–1365
- Hotta K, Nakata Y, Matsuo T, Kamohara S, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Masuzaki H, Yoneda M, Nakajima A, Miyazaki S, Tokunaga K, Kawamoto M, Funahashi T, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Nakao K, Sakata T, Matsuzawa Y, Tanaka K, Kamatani N, Nakamura Y (2008) Variations in the *FTO* gene are associated with severe obesity in the Japanese. *J Hum Genet* 53:546–553
- Kopelman PG (2000) Obesity as a medical problem. *Nature* 404:635–643
- Kumar J, Sunkishala RR, Karthikeyan G, Sengupta S (2007) The common genetic variant upstream of *INSIG2* gene is not associated with obesity in Indian population. *Clin Genet* 71:415–418
- Liu YJ, Liu XG, Wang L, Dina C, Yan H, Liu JF, Levy S, Papanicolaou CJ, Drees BM, Hamilton JJ, Meyre D, Delplanque J, Pei YF, Zhang L, Recker RR, Froguel P, Deng HW (2008) Genome-wide association scans identified *CTNBL1* as a novel gene for obesity. *Hum Mol Genet* 17:1803–1813
- Lyon HN, Emilsson V, Hinney A, Heid IM, Lasky-Su J, Zhu X, Thorleifsson G, Gunnarsdottir S, Walters GB, Thorsteinsdottir U, Kong A, Gulcher J, Nguyen TT, Scherag A, Pfeuffer A, Meitinger T, Bröner G, Rief W, Soto-Quiros ME, Avila L, Klanderman B, Raby BA, Silverman EK, Weiss ST, Laird N, Ding X, Groop L, Tuomi T, Isomaa B, Bengtsson K, Butler JL, Cooper RS, Fox CS, O'Donnell CJ, Vollmert C, Celedón JC, Wichmann HE, Hebebrand J, Stefansson K, Lange C, Hirschhorn JN (2007) The association of a SNP upstream of *INSIG2* with body mass index is reproduced in several but not all cohorts. *PLoS Genet* 3:627–633
- Maes HHM, Neale MC, Eaves LJ (1997) Genetic and environmental factors in relative body weight and human adiposity. *Behav Genet* 27:325–351
- Nielsen DM, Ehm MG, Weir BS (1998) Detecting marker-disease association by testing for Hardy–Weinberg disequilibrium at a marker locus. *Am J Hum Genet* 63:1531–1540
- Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Pérusse L, Bouchard C (2006) The human obesity gene map: the 2005 update. *Obesity* 14:529–644
- Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, Orrù M, Usala G, Dei M, Lai S, Maschio A, Busonero F, Mulas A, Ehret GB, Fink AA, Weder AB, Cooper RS, Galan P, Chakravarti A, Schlessinger D, Cao A, Lakatta E, Abecasis GR (2007) Genome-wide association scan shows genetic variants in the *FTO* gene are associated with obesity-related traits. *PLoS Genet* 3:1200–1210

- Smith AJP, Cooper JA, Li LK, Humphries SE (2007) INSIG2 gene polymorphism is not associated with obesity in Caucasian, Afro-Caribbean and Indian subjects. *Int J Obes* 31:1753–1755
- Tabara Y, Kawamoto R, Osawa H, Nakura J, Makino H, Miki T, Kohara K (2008) No association between INSIG2 Gene rs7566605 polymorphism and being overweight in Japanese population. *Obesity* 16:211–215
- Takaishi K, Duplomb L, Wang MY, Li J, Unger RH (2004) Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. *Proc Natl Acad Sci USA* 101:7106–7111
- Tanabe A, Yanagiya T, Iida A, Saito S, Sekine A, Takahashi A, Nakamura T, Tsunoda T, Kamohara S, Nakata Y, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Funahashi T, Miyazaki S, Tokunaga K, Hamaguchi K, Shimada T, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Matsuzawa Y, Kamatani N, Nakamura Y, Hotta K (2007) Functional single-nucleotide polymorphisms in the secretogranin III (SCG3) gene that form secretory granules with appetite-related neuropeptides are associated with obesity. *J Clin Endocrinol Metab* 92:1145–1154
- Wilson PWF, Grundy SM (2003) The metabolic syndrome: practical guide to origins and treatment: Part I. *Circulation* 108:1422–1425
- Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS (2003) Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. *Proc Natl Acad Sci USA* 100:3155–3160
- Yanagiya T, Tanabe A, Iida A, Saito S, Sekine A, Takahashi A, Tsunoda T, Kamohara S, Nakata Y, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Masuzaki H, Yoneda M, Nakajima A, Miyazaki S, Tokunaga K, Kawamoto M, Funahashi T, Hamaguchi K, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Nakao K, Sakata T, Matsuzawa Y, Kamatani N, Nakamura Y, Hotta K (2007) Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. *Hum Mol Genet* 16:3017–3026
- Yang L, Wu Y, Li H, Yu Z, Li X, Liu Y, Lin X, Chen Y (2008) Potential association of INSIG2 rs7566605 polymorphism with body weight in a Chinese subpopulation. *Eur J Hum Genet* 16:759–761
- Yoshiike N, Kaneda F, Takimoto H (2002) Epidemiology of obesity and public health strategies for its control in Japan. *Asia Pacific J Clin Nutr* 11:S727–S731

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)

Yasushi Saito^{a,*}, Mitsuhiro Yokoyama^b, Hideki Origasa^c, Masunori Matsuzaki^d,
Yuji Matsuzawa^e, Yuichi Ishikawa^f, Shinichi Oikawa^g, Jun Sasaki^h,
Hitoshi Hishidaⁱ, Hiroshige Itakura^j, Toru Kita^k, Akira Kitabatake^l,
Noriaki Nakaya^m, Toshiie Sakataⁿ, Kazuyuki Shimada^o, Kunio Shirato^p,

for the JELIS Investigators, Japan

^a Chiba University Graduate School of Medicine, Chiba, Japan

^b Hyogo Prefectural Awaji Hospital, Hyogo, Japan

^c University of Toyama, Toyama, Japan

^d Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

^e Sumitomo Hospital, Osaka, Japan

^f Kobe University Graduate School of Health Sciences, Kobe, Japan

^g Nippon Medical School, Tokyo, Japan

^h International University of Health and Welfare Graduate School, Fukuoka, Japan

ⁱ Fujita Health University School of Medicine, Aichi, Japan

^j Ibaraki Christian University, Ibaraki, Japan

^k Kyoto University Graduate School of Medicine, Kyoto, Japan

^l Kano General Hospital, Osaka, Japan

^m Nakaya Clinic, Tokyo, Japan

ⁿ Nakamura Gakuen University, Fukuoka, Japan

^o Jichi Medical University, Tochigi, Japan

^p Saito Hospital, Miyagi, Japan

Received 4 October 2007; received in revised form 3 June 2008; accepted 7 June 2008

Available online 19 June 2008

Abstract

Background: Japan EPA Lipid Intervention Study (JELIS) was a large-scale clinical trial examining the effects of eicosapentaenoic acid (EPA) on coronary artery disease (CAD) in hypercholesterolemic patients. Herein, we focused on risk factors other than low-density lipoprotein cholesterol (LDL-C) to investigate the effects of EPA on CAD among JELIS primary prevention cases.

Methods: Hypercholesterolemic patients on statin therapy but without evidence of CAD ($n = 14,981$) were randomly assigned to an EPA group ($n = 7503$) or a control group ($n = 7478$). The relationships between incident CAD, the number of CAD risk factors (hypercholesterolemia; obesity; high triglyceride (TG) or low high-density lipoprotein cholesterol (HDL-C); diabetes; and hypertension) and EPA treatment were investigated.

Results: For the control and EPA groups combined, a higher number of risk factors was directly associated with an increased incidence of CAD. Incidence was lower for the EPA group than for the control group regardless of the numbers of risk factors. Compared to patients with normal serum TG and HDL-C levels, those with abnormal levels (TG ≥ 150 mg/dL; HDL-C < 40 mg/dL) had significantly higher CAD hazard ratio (HR: 1.71; 95% CI: 1.11–2.64; $P = 0.014$). In this higher risk group, EPA treatment suppressed the risk of CAD by 53% (HR: 0.47; 95% CI: 0.23–0.98; $P = 0.043$).

* Corresponding author. Tel.: +81 43 290 2002; fax: +81 43 290 2011.

E-mail address: yasushi@faculty.chiba-u.jp (Y. Saito).

Conclusions: Multiple risk factors besides cholesterol are associated with markedly increased incidence of CAD. High TG with low HDL-C represents a particularly potent risk factor. EPA was effective in reducing the incidence of CAD events for patients with this dyslipidemic pattern, suggesting that EPA may be especially beneficial in patients who with abnormal TG and HDL-C levels (NCT00231738).
© 2008 Elsevier Ireland Ltd. All rights reserved.

Keywords: JELIS; Eicosapentaenoic acid; Primary prevention; Coronary artery disease; Risk factors; HDL-C; Triglycerides

1. Introduction

Eicosapentaenoic acid (EPA) is one of the n-3 polyunsaturated fatty acids (PUFA) found large quantities in fish oil. Ever since Dyerberg and Bang reported that EPA levels were high in the blood and diets of Greenland Inuit (who have low prevalence of atherosclerotic diseases [1]), the preventive effects of n-3 PUFA, including EPA, has been examined in many epidemiological and clinical studies [2–6]. Most studies have found that intake of fish and fish oil are related to reduced risk for total mortality, sudden death and coronary artery disease (CAD). Furthermore, randomized controlled intervention trials have suggested the suppressive effects of fish and fish oil consumption on CAD [7].

Using a highly purified ($\geq 98\%$) EPA, not a mixture of several fatty acids, i.e., fish oil, we conducted a randomized controlled trial, the Japan EPA Lipid Intervention Study (JELIS; ClinicalTrials.gov number, NCT00231738) [8], and reported that pure EPA suppressed CAD even in Japanese hypercholesterolemic patients who routinely consume a large amount of EPA and DHA from fish [5]. In the JELIS, EPA had no significant effect on total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) levels indicating that EPA can lower CAD risk by mechanisms other than LDL-C lowering.

Besides LDL-C, other risk factors for CAD include obesity, dyslipidemia, impaired glucose metabolism and hypertension. When present together in the same patients, these risk markers constitute a syndrome called the visceral fat syndrome, syndrome X, insulin-resistant syndrome and the metabolic syndrome [9–14]. Compared to patients with only one of these risk factors, incidence of CAD in patients with multiple factors is higher [15,16]. In addition, we assumed that EPA would suppress CAD even in patients at high risk. The present study focused on CAD risk associated with increasing numbers of non-LDL-C risk factors in hypercholesterolemic patients and the effects of EPA on the risk for CAD in these patients.

2. Materials and methods

2.1. Study design and patients

The study design of the JELIS, including inclusion and exclusion criteria, has been reported in detail [17]. Briefly, hypercholesterolemic patients with serum TC levels ≥ 250 mg/dL (men: 40–75 years; women: postmenopausal

75 years) were followed for up to 5 years (mean: 4.6 years) using the prospective, randomized, open-label, blinded end-point evaluation (PROBE) method. A total of 18,645 patients were registered and randomly assigned to either the EPA with statin (EPA group) or to statin alone (control group). Eighty percent ($n = 14,981$) of the patients had no history of CAD and are the subject of this report.

2.2. Procedures

Dietary guidance was provided for all patients before the start of and during the study. All patients received 10 mg of pravastatin or 5 mg of simvastatin administered once a day. In the EPA group, two 300-mg capsules containing EPA ethylester (EPA-E) with $> 98\%$ purity were administered 3 times/day, for a total daily dose of 1800 mg.

2.3. Primary endpoint

The primary endpoint was major coronary events (MCE), comprising: sudden cardiac death; fatal myocardial infarction; nonfatal myocardial infarction; unstable angina pectoris including hospitalization for documented ischemic episodes; and angioplasty/stenting or coronary artery bypass grafting. MCE was reported by primary physicians and was examined by the case report committee without knowledge of groups' assignment.

2.4. Risk factors

The following five risk factors were of primary interest for this report and were defined as indicated at the time of registration:

- A. Hypercholesterolemia:** untreated serum TC ≥ 250 mg/dL (all subjects in JELIS had serum TC ≥ 250 mg/dL).
- B. Obesity:** body mass index (BMI) ≥ 25 kg/m².
- C. Dyslipidemia:** serum triglyceride (TG) ≥ 150 mg/dL and/or high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL.
- D. Diabetes:** physician-diagnosis or fasting plasma glucose ≥ 126 mg/dL and/or hemoglobin A_{1c} $\geq 6.5\%$.
- E. Hypertension:** physician-diagnosis or systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.

Furthermore, all subjects were divided into the following four subgroups: based on the following serum TG and HDL-C levels at the time of registration:

1. TG <150 mg/dL and HDL-C \geq 40 mg/dL (low TG/high HDL-C group).
2. TG \geq 150 mg/dL and HDL-C \geq 40 mg/dL (high TG/high HDL-C group).
3. TG <150 mg/dL and HDL-C <40 mg/dL (low TG/low HDL-C group).
4. TG \geq 150 mg/dL and HDL-C <40 mg/dL (high TG/low HDL-C group).

2.5. Statistical analysis

All analyses were intention-to-treat with the level of significance set at $P < 0.05$ (two-sided). A Wilcoxon two-sample test was used to compare continuous variables. A chi-square test was used to compare class variables. Kaplan–Meier methods, the log-rank test, and the Cox proportional hazard model were used for survival analysis. The Cox proportional hazard model was adjusted for age, gender, smoking, diabetes and hypertension. However, we chose age, gender and smoking as adjusted factors to analyze the relationships between multiple risk factors and the incidence of MCE. We computed the power to detect the difference in CAD incidence between EPA and control groups for patients with high TG and low HDL-C. With a total of 957 patients in the high TG/low HDL-C group, we could detect a difference in MCE incidence of 1% vs. 0.5% with a power of 57%. The analysis plan for this sub-study was pre-specified according to the study hypothesis before the analysis was initiated. All analyses were conducted using SAS software (version 8.12; SAS Institute, Cary, NC).

3. Results

Subject characteristics have been previously reported [8]. The number of patients with hypertension and/or diabetes differed slightly from that originally published because the original designations were based only on physician-diagnosed diabetes or hypertension only. As a result, number of patients with diabetes was 1238 in control group, and 1258 in EPA group. In the same way, number of patients with hypertension was 4004 in control group, and 4015 in EPA group.

Risk for MCE increased in both the EPA and the control groups with increasing numbers of risk factors. The incidence of MCE was lower, but not statistically significant, for the EPA group than for the control group with each number of risk factors (Fig. 1).

Compared to the low TG/high HDL-C reference group, HR for MCE was increased only in the high TG/low HDL-C group (HR: 1.71; 95% CI: 1.11–2.64; $P = 0.014$; Fig. 2). Other risk factors were compared to the high TG/low HDL-C group, those in the low TG/high HDL-C group had no significant differences in TC or LDL-C but the proportions of male patients, smokers and drinkers; BMI; the prevalence of diabetes and high diastolic blood pressure. Furthermore,





Fig. 1. Multiple risk factors and the incidence of MCE. Number of risk factors at the time of registration was counted: Risk A, hypercholesterolemia (all patients); Risk B, body mass index (BMI) ≥ 25 ; Risk C, triglyceride ≥ 150 mg/dL or HDL-cholesterol <40 mg/dL; Risk D, diabetes; Risk E, hypertension. The Cox proportional hazard model was adjusted for age, gender, smoking. * $P < 0.05$ vs. risk number 1 in the control group.



TG and HDL-C (mg/dL)	Events	(%)	P	HR	95% CI
TG <150, HDL-C \geq 40	86 / 6614	1.3		1.00	
TG \geq 150, HDL-C \geq 40	97 / 6096	1.6	0.923	1.02	0.75 - 1.37
TG <150, HDL-C <40	4 / 196	2.0	0.663	1.26	0.46 - 3.46
TG \geq 150, HDL-C <40	32 / 957	3.3	0.014	1.71	1.11 - 2.64

Fig. 2. Incidence of MCE and triglyceride and HDL-cholesterol levels at the time of registration for the combined EPA and control group. Hazard ratio and P value adjusted for age, gender, smoking, diabetes, and hypertension. HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; HR, hazard ratio; CI, confidence interval.

Table 1
Patient background factors at time of registration and triglyceride and HDL-cholesterol levels

	TG < 150, HDL ≥ 40 (n = 6614)	TG ≥ 150, HDL < 40 (mg/dL) (n = 957)	P
Age (years)	61 ± 8	58 ± 9	<0.0001
Male (%)	1226 (19)	486 (51)	<0.0001
Smoker (%) ^a	697 (11)	312 (33)	<0.0001
Drinker (%) ^a	1170 (18)	336 (35)	<0.0001
BMI (kg/m ²)	23 ± 3	25 ± 3	<0.0001
Clinical history			
Diabetes ^b (%)	885 (13)	206 (22)	<0.0001
Hypertension ^c (%)	3297 (50)	508 (53)	0.062
Blood pressure			
Systolic (mmHg)	134 ± 18	135 ± 18	0.071
Diastolic (mmHg)	79 ± 11	80 ± 11	0.001
Lipid profile			
Total cholesterol (mg/dL)	274 ± 23	277 ± 30	0.779
LDL-cholesterol (mg/dL)	186 ± 28	186 ± 33	0.658
HDL-cholesterol (mg/dL)	67 ± 18	35 ± 4	<0.0001
Triglyceride (mg/dL) ^d	107 (85–128)	272 (207–399)	<0.0001
Fatty acid composition			
EPA (mol%)	3.1 ± 1.6	2.5 ± 1.5	<0.0001

Data represent number of patients (%) or mean (standard deviation), unless otherwise indicated.

^a Self-reported information.

^b Physician-diagnosed diabetes or fasting plasma glucose ≥ 126 mg/dL or hemoglobin A_{1c} ≥ 6.5%.

^c Physician-diagnosed hypertension or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.

^d Median (interquartile range). LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride.

in the high TG/low HDL-C group, EPA as a proportion of total plasma fatty acids at registration was lower than that in the reference group (Table 1). EPA treatment lowered the risk for MCE for the high-risk high TG/low HDL-C group by 53% (HR: 0.47; 95% CI: 0.23–0.98; $P=0.043$; Fig. 3). For the high-risk group, EPA did not affect TC, LDL-C or HDL-C, but it did reduce TG ($P=0.012$; Table 2). In addition, the mean plasma EPA levels in the high TG/low HDL-C group for the control group were 2.3 mol% at registration and 2.5 mol% during the observation period, whereas for the EPA group, mean plasma EPA levels markedly increased from 2.6 mol% at registration to 4.5 mol% during the observation

period (Table 2), and the high EPA concentrations remained throughout the observation period.

4. Discussion

LDL-C is an important risk factor for CAD, and statins have been shown to lower both LDL-C levels and risk for CAD [18,19]. Besides LDL-C, other risk factors such as obesity, dyslipidemia, impaired glucose metabolism and hypertension also increase risk for CAD [9–14]. This study examined the effects of EPA in the primary prevention sub-

Table 2
Risk factors in the high TG/low HDL-C group at follow-up

	TG ≥ 150 mg/dL and HDL-C < 40 mg/dL						P
	Control group (n = 475)			EPA group (n = 482)			
	Baseline	Observation period	Change from baseline (%)	Baseline	Observation period	Change from baseline (%)	
Blood pressure							
Systolic (mmHg)	136 ± 18	134 ± 14	0	134 ± 17	134 ± 14	0	0.700
Diastolic (mmHg)	81 ± 11	79 ± 9	-2	79 ± 10	78 ± 9	-1	0.159
Lipid profile							
Total cholesterol (mg/dL)	277 ± 29	229 ± 37	-17	276 ± 32	229 ± 35	-17	0.522
LDL-cholesterol (mg/dL)	185 ± 30	140 ± 35	-22	187 ± 35	142 ± 35	-20	0.129
HDL-cholesterol (mg/dL)	35 ± 4	42 ± 9	22	35 ± 4	42 ± 9	22	0.776
Triglyceride (mg/dL) ^a	277 (215–400)	218 (166–291)	-18	269 (201–399)	202 (150–271)	-23	0.012
Fatty acid composition							
EPA (mol%)	2.3 ± 1.3	2.5 ± 1.2	28	2.6 ± 1.6	4.5 ± 1.9	120	<0.0001

Data represent mean (standard deviation), unless otherwise indicated.

^a Median (interquartile range). LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride.




Fig. 3. Effects of EPA on the incidence of MCE for the high TG/low HDL-C group. Hazard ratio and *P* value adjusted for age, gender, smoking, diabetes, and hypertension. HR, hazard ratio; CI, confidence interval.

group of JELIS as a function of other CAD risk factors obesity; dyslipidemia; diabetes; and hypertension. In both the control and EPA groups, greater number of risk factors was associated with increased incidence of MCE. This indicates that risk for MCE in the JELIS involved risk factors other than LDL-C. When dividing subjects with a number of risk accumulations among the 5 risk factors, incidence of MCE for the EPA group was lower than that for the control group for all subjects combined, regardless of the number of risk factors. But these differences were not statistically significant, most likely due to the low *n* in each subcategory.

EPA suppresses TG synthesis in the liver and thereby lowers serum TG levels and decreases atherogenic lipoproteins such as remnants and small dense LDL (sdLDL) [20]. Consequently, we compared MCE rates in the high TG/low HDL-C group to those in the low TG/high HDL-C reference group at the time of registration and found them to be increased by 71%. This shows that high TG/low HDL-C patients are at increased risk for MCE. Furthermore, within the high TG/low HDL-C group, EPA administration markedly reduced risk for MCE by 53%. When comparing patient background factors at the time of registration between these two groups, no significant differences in TC or LDL-C were seen, but the ratio of male patients, ratio of smokers and drinkers, BMI, incidence of diabetes and diastolic blood pressure for the high TG/low HDL-C group were all significantly higher. Thus, this group had many other features of the metabolic syndrome besides just high TG and low HDL-C. The present results also suggest that EPA is effective for suppressing onset of MCE in groups with multiple risk factors. Interestingly, plasma EPA level for the high TG/low HDL-C group at the time of registration was significantly lower when compared to the low TG/high HDL-C group. These results suggest some pre-existing baseline association between multiple risk factors and low plasma EPA levels, even in a Japanese population with high fish intake.

In the present study, EPA treatment had no effect on LDL-C in the high TG/low HDL-C group during the follow-up period, indicating that the lower MCE rates were the result of other effects of EPA than lowering LDL-C. EPA has many beneficial effects [21,22], including antiplatelet activity [23] and plaque-stabilizing properties [24,25], and thus these were likely responsible, at least in part, for the reductions in MCE.

While risk reduction in all primary prevention subjects of JELIS was 18% [8], risk reduction by 53% was achieved in high TG/low HDL-C group. This suggests that the factors that EPA appears to influence (plaque destabilization, rupture, and formation of occlusive thrombus) may be especially important mechanisms of MCE in patients with this form of dyslipidemia. EPA administration to the high TG/low HDL-C group slightly lowered TG and did not change in HDL-C. Although the effects of EPA on serum TG and HDL-C were limited, EPA markedly suppressed MCE in the high TG/low HDL-C group, and this suggests that EPA acts on mechanisms upstream of high TG/low HDL-C to suppress multiple risks.

Metabolic syndrome has been noted as a new risk factor for CAD [9,10]. Metabolic syndrome is characterized by accumulation of risk factors such as hypertension, dyslipidemia and impaired glucose metabolism on the basis of visceral fat accumulation. In the present study, high TG and low HDL-C levels (the components of the metabolic syndrome) were shown to be important risk factors for MCE. EPA was most effective in the high TG/low HDL group in reducing incidence of MCE. Hence, this particular patient population may benefit the most from EPA treatment. Satoh et al. administered 1800 mg/day of EPA-E (the same dose as the JELIS) for 3 months to type II diabetics with the metabolic syndrome and reported that levels of sdLDL and remnant lipoproteins, which are risk factors for new cardiovascular events [26], decreased, and that levels of plasma C-reactive protein (CRP), a marker of inflammation that has been examined as a risk factor for cardiovascular events [27], also decreased [20]. In addition, Itoh et al. reported that the same regimen increased adiponectin [28], an adipocytokine known to improve arteriosclerosis [29] and diabetes [30].

The present results among JELIS primary prevention cases showed that multiple risk factors increase the risk of MCE. For the high TG/low HDL-C group, risk of MCE was particularly high, and EPA was shown to potently suppress MCE. In the high TG/low HDL-C group, level of plasma EPA at the time of registration was low, but EPA administration increased plasma levels, suggesting some correlation between plasma EPA level and MCE risk.

Acknowledgments

This study was supported by grants from Mochida Pharmaceutical Co. Ltd., Tokyo, Japan. We thank all trial participants and the large numbers of doctors, nurses, and hospital staff who made long-term commitments to the study.

References

- [1] Dyerberg J, Bang HO, Stoffensen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? *Lancet* 1978;2:117–9.
- [2] Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* 1989;2:757–61.
- [3] Davi GL, Stamler J, Orenca AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. *N Engl J Med* 1997;336:1046–53.
- [4] Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. *JAMA* 2002;287:1815–21.
- [5] Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. *Circulation* 2006;113:195–202.
- [6] Morris MC, Manson JE, Rosner B, et al. Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. *Am J Epidemiol* 1995;142:166–75.
- [7] Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet* 1999;354:447–55.
- [8] Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* 2007;369:1090–8.
- [9] Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. *Lancet* 2005;366:1059–62.
- [10] Arai H, Yamamoto A, Matsuzawa Y, et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. *J Atheroscler Thromb* 2006;13:202–8.
- [11] DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diab Care* 1991;14:173–94.
- [12] Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med* 1989;149:1514–20.
- [13] Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. *Atherosclerosis* 1994;107:239–46.
- [14] Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988;37:1595–607.
- [15] Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709–16.
- [16] Ohnishi H, Saitoh S, Takagi S, et al. Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu Study. *Diab Obes Metab* 2005;7:83–7.
- [17] Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). *Am Heart J* 2003;146:613–20.
- [18] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;339:1349–57.
- [19] Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995;333:1301–7.
- [20] Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. *Diab Care* 2007;30:144–6.
- [21] Harris WS, Park Y, Isley WL. Cardiovascular disease and long-chain omega-3 fatty acids. *Curr Opin Lipidol* 2003;14:9–14.
- [22] Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment. *BMJ* 2004;328:30–5.
- [23] Tamura Y, Hirai A, Terano T, et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. *Prog Lipid Res* 1986;25:461–6.
- [24] Kawano H, Yano T, Mizuguchi K, Mochizuki H, Saito Y. Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells smooth muscle cells and fibrous components in rabbits caused by all-*cis*-5,8,11,14,17-icosapentaenoic acid. *J Atheroscler Thromb* 2002;9:170–7.
- [25] Thies F, Garry JM, Yaquob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. *Lancet* 2003;361:477–85.
- [26] Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. *Circulation* 2004;109:III2–7.
- [27] Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. *Am J Cardiol* 2003;92:17K–22K.
- [28] Itoh M, Suganami T, Satoh N, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. *Arterioscler Thromb Vasc Biol* 2007;27:1918–25.
- [29] Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. *Circulation* 2002;106:2767–70.
- [30] Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci USA* 2001;98:2005–10.